Compare Enveric Biosciences Inc (ENVB) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Illinois Tool Works Inc. — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Illinois Tool Works Inc. trades at $281.57 (market cap $78.08B). The key difference: Illinois Tool Works Inc. is far larger — about 14676.7× Enveric Biosciences Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ITW | |
|---|---|---|
Market Cap | $5.32M | $78.08B |
Sector | Health | Industrials |
52-Week High | $17.40 | $299.60 |
52-Week Low | $1.28 | $241.07 |
Enterprise Value | $408.82K | $86.41B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
ITW trades at $280.84, up 3.14% with a bullish technical signal and strong earnings beats. The company maintains robust profitability with a 19.32% net margin and 96.88% ROE. Recent Q1 2026 results exceeded expectations with EPS of $2.66, and the upcoming Q2 report on July 28, 2026, is highly anticipated. Dividend payments continue steadily, reinforcing shareholder returns amid modest revenue growth projections.
Outlook remains positive with a consensus price target of $288.25, though risks include construction sector weakness and currency headwinds. The stock's high valuation multiples (P/E 25.2) require sustained earnings growth to justify further upside, while analyst sentiment is mixed with only 21% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
